- Cerus (NASDAQ:CERS +2.9%) consummates a $30M growth capital credit facility with Oxford Finance LLC. The company received $10M yesterday and has the option of drawing another $10M upon FDA approval of the Intercept Blood System for either platelets or plasma. The approval will trigger the last $10M tranche which will be available at Cerus' option between July 1, 2015 and December 31, 2015.
Cerus secures capital
Recommended For You
More Trending News
About CERS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CERS | - | - |
Cerus Corporation |